|Bid||1.1600 x 3200|
|Ask||0.0000 x 4000|
|Day's Range||1.4000 - 1.4900|
|52 Week Range||1.2000 - 2.2300|
|Beta (3Y Monthly)||0.77|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 4, 2019 - Nov 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.50|
CLEVELAND, Aug. 07, 2019 -- Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended June 30, 2019. Highlights of the second quarter of.
CLEVELAND, July 08, 2019 -- Athersys, Inc. (Nasdaq: ATHX) will release its second quarter 2019 financial results at approximately 4:00 PM Eastern Time on Wednesday, August 7,.
Dr. James Kovach's career has spanned from professional football to patent law and startups. His latest challenge? Aggie Square.
Athersys, Inc. (ATHX) announced today that Dr. Gil Van Bokkelen, Chairman and CEO, will present at the Jefferies 2019 Healthcare Conference taking place June 4-7, 2019 in New York City. Dr. Van Bokkelen’s presentation will take place at 11 AM Eastern Time on June 7, 2019 and will focus on the Company’s mission and the clinical development of its MultiStem® cell therapy. The talk will also summarize the recent positive data from its exploratory Phase 1/2 clinical study evaluating MultiStem cell therapy for the treatment acute respiratory distress syndrome (ARDS), and the ARDS clinical program has received Fast Track designation from the U.S. Food and Drug Administration for the next phase of development.
CLEVELAND, May 28, 2019 -- Athersys, Inc. (NASDAQ: ATHX) announced today its participation in several sessions at this year’s International Society for Cell and Gene Therapy.
While it may not be enough for some shareholders, we think it is good to see the Athersys, Inc. (NASDAQ:ATHX) share...
Athersys, Inc. (ATHX) announced additional favorable data from its exploratory Phase 1/2 acute respiratory distress syndrome (ARDS) clinical trial. Dr. Geoff Bellingan, Medical Director at University College London Hospitals, described the data from the clinical trial, referred to as the MUST-ARDS trial, during his presentation today at the American Thoracic Society International Conference in Dallas, Texas, the longest running, large-scale conference in the world offering groundbreaking research in pulmonary, critical care and sleep medicine.
Biotech stocks came under pressure this week along with the broader market, which succumbed to the negative sentiment generated by U.S.-China trade tensions. However, they recouped some of these losses, ...
CLEVELAND, May 08, 2019 -- Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended March 31, 2019. Highlights of the first quarter of.
NEW YORK, NY / ACCESSWIRE / May 8, 2019 / Athersys, Inc. (NASDAQ: ATHX ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 8, 2019 at 4:30 PM Eastern Time. ...
Athersys (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
Athersys, Inc. (ATHX) announced today that its partner, HEALIOS K.K. (“Healios”), has enrolled the first patient in its ONE-BRIDGE study in Japan, evaluating MultiStem® cell therapy treatment of patients who suffer from acute respiratory distress syndrome (“ARDS”). The clinical trial investigates the efficacy and safety of MultiStem therapy for patients with pneumonia-induced ARDS.
Athersys, Inc. (ATHX) announced today that the company will host an investor day on Tuesday, May 14, 2019. The investor day will include presentations from the Company’s management team as well as experts in the fields of stroke and ARDS. Dr. David Chiu, MD, FAHA, Medical Director at the Eddy Scurlock Stroke Center at Houston Methodist Hospital will be discussing the MASTERS-2 clinical trial for stroke.
CLEVELAND, April 10, 2019 -- Athersys, Inc. (Nasdaq: ATHX) will release its first quarter 2019 financial results at approximately 4:00 PM Eastern Time on Wednesday, May 8,.